Labcorp Receives FDA Approval for BRAF Melanoma Diagnostic
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Labcorp has announced that the FDA has approved its companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
This approval supports the treatment of patients with advanced melanoma, enhancing Labcorp's capabilities in precision medicine.
Labcorp
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma”
SEC Filing — Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
SupportCorroborates it
“The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.”
fierce biotech — <a href="/medtech/labcorp-nabs-fda-green-light-braf-melanoma-diagnostic" hreflang="en">Labcorp nabs FDA green light for BRAF melanoma diagnostic </a>